Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PRIME Scheme: EMA To Tackle Problem Of Premature Marketing Applications

‘Toolbox’ Guidance Is Also Being Finalized

Executive Summary

After finding that products developed under the PRIME scheme frequently lost their accelerated status while they were being reviewed for potential EU marketing approval, the European Medicines Agency is looking into whether it should start holding “submission readiness” meetings.

You may also be interested in...



Major Review Of EU PRIME Scheme Highlights Faster Approvals

Products developed under PRIME, the European Medicines Agency’s priority medicines scheme, are more likely to be granted accelerated assessment and maintain fast-track status than non-PRIME products, says a new report.

PRIME: How The EU Scheme Is Delivering On Promise Of Faster Drug Approvals

Nineteen new products that were developed under PRIME, the European Medicines Agency’s priority medicines scheme, are now approved for use in the EU. Pink Sheet analysis finds that many were reviewed much faster than they would have been under standard review timelines.

EMA Tells Companies How To Boost Their Approval Chances Under PRIME

Companies find it challenging when it comes to preparing robust quality data packages for their marketing applications for investigational products that have made it onto the European Medicines Agency’s popular priority medicines scheme.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145831

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel